| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President & CEO
1 company
David Renzi last filed a Form 4 in November 2016, as President & CEO at KALV. David Renzi's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
David Renzi has 4 Form 4 filings on record from August 2015 to November 2016, all as President & CEO at KalVista Pharmaceuticals (KALV), 2015–2016.
The 7 reported transactions were 2 option exercises, 2 option or other derivative awards, 1 tax withholding and 1 tender, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $37K.
The only open-market sale was 10,000 shares of KALV at an average $3.70 on December 30, 2015, about $37K.
Shares as reported in the last Form 4 for each company; the most recent is from November 2016. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2015 | KALV Kalvista Pharmaceuticals, Inc. | President & CEO | Sale+OE | 10,000 | $3.70 | $37,000.00 | - |